Prime Medicine Inc. (NASDAQ:PRME) is a hot penny stock to invest in, with BMO Capital analyst maintaining a Buy rating and setting a $10.00 price target based on innovative gene editing technology. The company recently secured $39 million in funding from the Cystic Fibrosis Foundation for its prime editing platform. Prime Medicine Inc. has achieved a notable 90% editing efficiency in the second patient treated ex vivo, reducing risk and increasing credibility. The company, headquartered in Cambridge, MA, develops one-time curative genetic therapies. While PRME shows promise, certain AI stocks may offer greater upside potential and less downside risk. For more information, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT